Denali Therapeutics
DNLI · Nasdaq · United States
Share price · DNLI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when DNLI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+7.8%
- 14 Oct 2026-2.9%
Nothing announced by DNLI that day or the session before.
- 14 Jul 2026-14.5%
Nothing announced by DNLI that day or the session before.
- 15 Apr 2026+7.5%
Nothing announced by DNLI that day or the session before.
- 26 Mar 2026-12.2%
- 22 Jan 2026+12.5%
Nothing announced by DNLI that day or the session before.
- 6 Jan 2026+7.4%
- 10 Dec 2025-10.6%
Share of unusual movement by asset
For each asset, the share of DNLI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
Tividenofusp alfa(Avlayah) | Approved | Iduronate-2-sulfatase (IDS)Protein / enzyme therapeutic | Mucopolysaccharidosis Type II |
| Phase 3 | LRRK2Small molecule | Parkinson's Disease | |
| Phase 1/2 | SGSH replacement (TfR-mediated brain delivery)Protein / enzyme therapeutic | Mucopolysaccharidosis Type IIIA | |
| Phase 1 | MAPT mRNA (RNAi/ASO)RNA / oligonucleotide | Alzheimer's Disease |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2031 (1)
February 2031 (1)
What to watch
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $18M | $106M | $106M+ $413M short-term inv. | —-$117M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $3.6M | $97M | $205M+ $509M short-term inv. | $128M-$97M operating cash flow | report ↗ |
| 2026-Q1 | — | $104M | $391M+ $600M short-term inv. | $128M-$131M operating cash flow | report ↗ |
| 2025-Q3 | — | $102M | $94M+ $757M short-term inv. | $127M-$107M operating cash flow | report ↗ |
| 2025-Q2 | — | $103M | $144M+ $758M short-term inv. | $124M-$75M operating cash flow | report ↗ |
| 2025-Q1 | — | $116M | $60M+ $761M short-term inv. | $133M-$131M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $98M | $92M+ $746M short-term inv. | $107M-$59M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $91M | $76M+ $821M short-term inv. | $99M-$91M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $107M | $62M+ $876M short-term inv. | $102M-$114M operating cash flow | report ↗ |
| 2023-Q3 | $1.3M | $90M | $150M+ $961M short-term inv. | $99M-$87M operating cash flow | report ↗ |
| 2023-Q2 | $294M | $98M | $134M+ $1.1B short-term inv. | —-$113M operating cash flow | report ↗ |
| 2023-Q1 | $35M | $129M | $70M+ $1.2B short-term inv. | $110M-$59M operating cash flow | report ↗ |
| 2022-Q3 | $0.2M | $88M | $120M+ $987M short-term inv. | $103M-$57M operating cash flow | report ↗ |
| 2022-Q2 | $52M | $93M | $157M+ $914M short-term inv. | $59M-$43M operating cash flow | report ↗ |
| 2022-Q1 | $42M | $86M | $106M+ $853M short-term inv. | $65M-$72M operating cash flow | report ↗ |
| 2021-Q3 | $5.3M | $72M | $396M+ $645M short-term inv. | $85M-$41M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $419M | $208M+ $663M short-term inv. | $128M-$413M operating cash flow | report ↗ |
Denali reported revenue of $0M for 2025 (prior year $0M), R&D spend of $418.78M, up 5.6% YoY, and cash and equivalents of $208.43M, with total cash, cash equivalents and marketable securities of approximately $966.2M as of December 31, 2025. The company posted a full-year net loss of $512.54M, including a fourth-quarter net loss of $128.5M.
Denali established commercial launch readiness for tividenofusp alfa ahead of an April 5, 2026 PDUFA target action date for Hunter syndrome, and presented preliminary Phase 1/2 data for DNL126 supporting an accelerated approval path in Sanfilippo syndrome type A. Start-up activities are underway for DNL628 in Alzheimer’s disease and DNL952 in late-onset Pompe disease, with additional expected readouts including BIIB122 LUMA data in mid-2026 and eclitasertib Phase 2 results in the first half of 2026. Management expects to advance four to six additional programs into the clinic over the next three years, and the company completed a $275.0M synthetic royalty funding agreement with Royalty Pharma and a public offering totaling approximately $200.0M in net proceeds.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $396M | $177M+ $657M short-term inv. | $106M-$348M operating cash flow | report ↗ |
| 2023-FY | $331M | $424M | $129M+ $907M short-term inv. | $36M-$358M operating cash flow | report ↗ |
| 2022-FY | $105M | $359M | $220M+ $1.1B short-term inv. | $82M-$245M operating cash flow | report ↗ |
| 2021-FY | $49M | $265M | $295M+ $572M short-term inv. | $73M-$211M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 7 sales ($1.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Schuth Alexander O. · COFO and Secretary | Option exercise | 16,566 | $9.60 | $159K | Form 4 |
| 2026-11-17 | Schuth Alexander O. · COFO and Secretary | Option exercise (derivative) | 16,566 | — | — | Form 4 |
| 2026-09-04 | Chin Peter Scott · Chief Medical Officer | Open-market sale | 1,654 | $22.29 | $37K | Form 4 |
| 2026-09-02 | Thornberry Nancy · director | Open-market sale | 10,824 | $22.85 | $247K | Form 4 |
| 2026-09-02 | Thornberry Nancy · director | Open-market sale | 615 | $23.74 | $15K | Form 4 |
| 2026-09-01 | Schuth Alexander O. · COFO and Secretary | Open-market sale | 2,768 | $23.44 | $65K | Form 4 |
| 2026-08-12 | Watts Ryan J. · director, President and CEO | Gift | 32,220 | — | — | Form 4 |
| 2026-08-11 | Schuth Alexander O. · COFO and Secretary | Open-market sale | 2,857 | $25.07 | $72K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 266 reporting institutions held 147.8M shares ($2.6B, 92.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 13,034,434 | $250.3M |
| 2 | BAILLIE GIFFORD & CO | 12,066,479 | $231.7M |
| 3 | Temasek Holdings (Private) Ltd | 7,012,974 | $134.6M |
| 4 | STATE STREET CORP | 6,272,001 | $120.4M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 6,147,957 | $118.0M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,120,160 | $117.5M |
| 7 | FMR LLC | 4,575,374 | $87.8M |
| 8 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4,432,314 | $85.1M |
| 9 | GOLDMAN SACHS GROUP INC | 4,407,255 | $84.6M |
| 10 | BAKER BROS. ADVISORS LP | 3,731,695 | $71.6M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 3,727,114 | $71.6M |
| 12 | Holocene Advisors, LP | 3,195,429 | $61.4M |
| 13 | DIMENSIONAL FUND ADVISORS LP | 2,692,175 | $51.7M |
| 14 | UBS Group AG | 2,571,344 | $49.4M |
| 15 | Pictet Asset Management Holding SA | 2,558,865 | $48.4M |